Mucopolysaccharidoses [clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6]
clinicaltrials:NCT01330277Longitudinal Study of Bone Disease in Children With Mucopolysaccharidoses (MPS) I, II, and VI [clinicaltrials:NCT01521429]Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network [clinicaltrials:NCT01586871]Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics [clinicaltrials:NCT01675674]
condition [clinicaltrials_vocabulary:condition]
Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) [clinicaltrials:NCT00004454]Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [clinicaltrials:NCT00005900]Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI [clinicaltrials:NCT00048620]Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI [clinicaltrials:NCT00048711]Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI [clinicaltrials:NCT00067470]clinicaltrials:NCT00069641Study of rhASB in Patients With Mucopolysaccharidosis VI [clinicaltrials:NCT00104234]A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients [clinicaltrials:NCT00144768]clinicaltrials:NCT00144781Mucopolysaccharidosis I (MPS I) Registry [clinicaltrials:NCT00144794]clinicaltrials:NCT00146757clinicaltrials:NCT00146770Stem Cell Transplant w/Laronidase for Hurler [clinicaltrials:NCT00176891]clinicaltrials:NCT00176917Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP) [clinicaltrials:NCT00214773]clinicaltrials:NCT00215527clinicaltrials:NCT00258011clinicaltrials:NCT00299000A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants [clinicaltrials:NCT00418821]clinicaltrials:NCT00607386clinicaltrials:NCT00630747Intrathecal Enzyme Replacement for Hurler Syndrome [clinicaltrials:NCT00638547]clinicaltrials:NCT00654433Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products [clinicaltrials:NCT00695279]clinicaltrials:NCT00741338clinicaltrials:NCT00748969Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I [clinicaltrials:NCT00786968]A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome) [clinicaltrials:NCT00787995]clinicaltrials:NCT00852358clinicaltrials:NCT00884949clinicaltrials:NCT00912925clinicaltrials:NCT01043640Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis [clinicaltrials:NCT01238328]A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [clinicaltrials:NCT01242111]clinicaltrials:NCT01275066To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients [clinicaltrials:NCT01301898]clinicaltrials:NCT01330277Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [clinicaltrials:NCT01415427]Intracerebral Gene Therapy for Sanfilippo Type A Syndrome [clinicaltrials:NCT01474343]Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) [clinicaltrials:NCT01509768]
condition browse [clinicaltrials_vocabulary:condition-browse]
Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) [clinicaltrials:NCT00004454]Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [clinicaltrials:NCT00005900]Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI [clinicaltrials:NCT00048620]Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI [clinicaltrials:NCT00048711]Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI [clinicaltrials:NCT00067470]clinicaltrials:NCT00069641Study of rhASB in Patients With Mucopolysaccharidosis VI [clinicaltrials:NCT00104234]A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients [clinicaltrials:NCT00144768]clinicaltrials:NCT00144781Mucopolysaccharidosis I (MPS I) Registry [clinicaltrials:NCT00144794]clinicaltrials:NCT00146757clinicaltrials:NCT00146770Stem Cell Transplant w/Laronidase for Hurler [clinicaltrials:NCT00176891]clinicaltrials:NCT00176917Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP) [clinicaltrials:NCT00214773]clinicaltrials:NCT00215527clinicaltrials:NCT00258011clinicaltrials:NCT00299000A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants [clinicaltrials:NCT00418821]clinicaltrials:NCT00607386clinicaltrials:NCT00630747Intrathecal Enzyme Replacement for Hurler Syndrome [clinicaltrials:NCT00638547]clinicaltrials:NCT00654433Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products [clinicaltrials:NCT00695279]clinicaltrials:NCT00741338clinicaltrials:NCT00748969Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I [clinicaltrials:NCT00786968]A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome) [clinicaltrials:NCT00787995]clinicaltrials:NCT00852358clinicaltrials:NCT00884949clinicaltrials:NCT00912925clinicaltrials:NCT01043640Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis [clinicaltrials:NCT01238328]A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [clinicaltrials:NCT01242111]clinicaltrials:NCT01275066To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients [clinicaltrials:NCT01301898]clinicaltrials:NCT01330277Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [clinicaltrials:NCT01415427]Intracerebral Gene Therapy for Sanfilippo Type A Syndrome [clinicaltrials:NCT01474343]Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) [clinicaltrials:NCT01509768]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Mucopolysaccharidoses [clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6]
Bio2RDF identifier
756327df5c81fdf20eadc33d0740d1c6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6
identifier
clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6
title
Mucopolysaccharidoses
@en
type
label
Mucopolysaccharidoses [clinicaltrials_resource:756327df5c81fdf20eadc33d0740d1c6]
@en
Mucopolysaccharidoses